| Name | Title | Contact Details |
|---|
Cameron Hall Assisted Living is a Canton, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Worldwide Clinical Trials is a global CRO providing full-service drug development services to the pharmaceutical and biotechnology industries from Early Phase and Bioanalytical Sciences through Phase II and III trials to peri-approval studies. Our team offers clients a wealth of expertise in neuroscience, cardiovascular, inflammation, rare disease, and other therapeutic areas. We successfully manage clinical trials with our own staff across nearly 60 countries in North America, Latin America, Europe, Asia Pacific and Middle East. Our full-service capabilities enable us to meet particular trial requirements without compromising on science, safety or service. Bioanalytical • Method Transfer and Validation • Pharmacokinetic Analysis and Reporting Clinical Research Services • Clinical Pharmacology • Bridging Studies • Dyna-Bridging Studies • Drug-Drug Interactions • Pharmacodynamic Modeling Clinical Development • Protocol Development • Feasibility • Project Management • Medical Monitoring • Clinical Monitoring • Site Management • Data Management • Rater Training • Biostatistics and Data Analysis • Medical Writing • Regulatory Affairs • Quality Assurance • Drug and Supply Depots • Drug Safety Peri-Approval • Product Safety and Pharmacovigilance • Late-Stage Research • Registries and Observational Studies • Health Outcomes, Epidemiology and Risk Management
Cactus Health Systems is a Guelph, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Custom Spine Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Parsippany, NJ. To find more information about Custom Spine Inc, please visit www.customspine.com